PegaGen (pegfilgrastim biosimilar) / CinnaGen - LARVOL DELTA

Evaluating the safety and effectiveness of PegaGen (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study. (PubMed, Support Care Cancer) - P | "The results from this post-marketing surveillance study support the safety and effectiveness of PegaGen used for the prevention of chemotherapy-induced FN in patients with various types of cancer and treatment regimens."

Journal • P4 data • Breast Cancer • Chemotherapy-Induced Neutropenia • Febrile Neutropenia • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hematological Malignancies • Lymphoma • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Solid Tumor

Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN (clinicaltrials.gov) - P; N=654; Completed; Sponsor: Cinnagen

Clinical • New trial • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology